Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $54.2M | $76.7M | $314M | $478M | $251M | $227M | $170M |
| Revenue growth | — | 41.5% | 309.4% | 52.2% | -47.4% | -9.7% | -25.1% |
| Operating income | -$71.6M | -$137M | -$1.83B | -$2.21B | -$864M | -$560M | -$315M |
| Operating margin | -132.1% | -178.8% | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Net income | -$119M | -$127M | -$1.83B | -$2.10B | -$893M | -$547M | -$313M |
| Net margin | -220.2% | -165.2% | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (diluted) | -$0.10 | -$0.10 | -$1.39 | -$50.20 | -$18.37 | -$10.54 | -$5.64 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.7M | -$136M | -$254M | -$252M | -$296M | -$320M | -$171M |
| Capital expenditures | $22.2M | $57.8M | $56.5M | $52.3M | $40.8M | $62.5M | $7.67M |
| Free cash flow | -$66.9M | -$194M | -$310M | -$304M | -$336M | -$382M | -$179M |
| Share buybacks | $408K | — | — | — | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $495M | $381M | $1.55B | $1.32B | $944M | $562M | $167M |
| Total assets | — | $675M | $2.07B | $2.54B | $1.67B | $1.38B | $1.12B |
| Total liabilities | — | $205M | $504M | $803M | $568M | $661M | $611M |
| Shareholders' equity | $502M | $461M | $1.51B | $1.74B | $1.10B | $716M | $509M |
| Retained earnings | — | -$468M | -$2.30B | -$4.40B | -$5.29B | -$5.84B | -$6.15B |
| Shares (wtd avg diluted) | 1.15B | 1.27B | 1.36B | 42.0M | 48.6M | 51.9M | 55.5M |
Every figure is extracted from Ginkgo Bioworks Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.